Regnum
$0
5
+$0+0% Thursday 20:00
统计数据
当日最高
0
当日最低
0
52周最高
0.05
52周最低
0
成交量
600
平均成交量
0
市值
2,295
市盈率
-
股息收益率
-
股息
-
收益
30Sep预期
预期每股收益
N/A
实际每股收益
-0.0043
人们还关注
此列表基于关注RGMP的Stock Events用户的观察列表。这不是投资建议。
竞争者
这个列表是基于最近市场事件的分析。这不是投资建议。
关于
Manufacturing
Consumer Services
Movies/Entertainment
Software and Other Prerecorded Compact Disc, Tape, and Record Reproducing
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
Show more...
首席执行官
员工
1
国家
US
ISIN
US75915R1068